NCT07374003 2026-01-28
Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT04229459 2026-01-14
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Rabin Medical Center
Phase 2 Active not recruiting
NCT07339488 2026-01-14
ILDR-03
Shantou University Medical College
Phase 2 Active not recruiting
NCT03712566 2026-01-08
MASST
University Health Network, Toronto
Active not recruiting
NCT05659251 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT05189730 2025-11-20
ETNT
Sichuan Cancer Hospital and Research Institute
Phase 2 Active not recruiting
NCT06281886 2025-11-17
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06143748 2025-09-17
EC-CRT-006
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07147361 2025-08-29
PB-PD1R-SCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Active not recruiting
NCT07142421 2025-08-26
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT06020885 2025-07-21
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
Sun Yat-sen University
Phase 1 Active not recruiting
NCT07074535 2025-07-20
CT and Endoscopic Biopsy Image-Based Deep Learning for Predicting Left Recurrent Laryngeal Nerve Lymph Node Metastasis in Esophageal Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Active not recruiting
NCT04666090 2025-05-15
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT06762158 2025-01-07
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
RenJi Hospital
Phase NA Active not recruiting
NCT05520619 2024-11-18
EC-CRT-002
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04584008 2024-10-15
VISIONARY
Peking University
Phase NA Active not recruiting
NCT06410677 2024-05-13
CMECC
Changhai Hospital
Active not recruiting
NCT04764227 2023-08-03
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Fudan University
Phase 2 Active not recruiting
NCT05951127 2023-07-18
LEO
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Active not recruiting
NCT01688908 2018-01-23
ESECC
Peking University
Phase NA Active not recruiting